Current Liabilities
Pfizer·Balance Sheet Statement·12 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total current liabilities | $43.8B | $43.2B | $43.0B | $36.5B | $37.7B | $36.6B | $37.0B | $34.3B |
| Other accrued liabilities | $16.4B | $19.9B | $19.7B | $20.0B | $18.6B | $19.5B | $19.4B | $20.1B |
| Accounts payable | $5.1B | $5.3B | $5.6B | $5.2B | $5.2B | $5.0B | $5.2B | $4.5B |
| Total Debt, Gross | $12.0B | $9.8B | $7.0B | $4.5B | $4.3B | $4.3B | $3.2B | $3.9B |
| Current portion of long-term debt | $3.7B | $3.7B | $3.7B | $3.7B | $4.2B | $4.2B | $3.0B | $3.9B |
| Income taxes payable | $2.9B | $2.9B | $2.9B | $3.1B | $3.7B | $3.8B | $3.1B | $3.1B |
| Accrued Manufacturing Costs | $2.6B | $3.4B | $3.8B | $2.6B | $2.4B | $3.0B | $3.6B | $2.7B |
| Compensation and benefits | $2.6B | $3.4B | $3.8B | $2.6B | $2.4B | $3.0B | $3.6B | $2.7B |
| Derivative Liabilities - Fair Value | $1.2B | $1.5B | $1.4B | $1.3B | $1.9B | $1.6B | $1.5B | $1.4B |
| Supplier Finance Program Obligations | $593.0M | $628.0M | $688.0M | $546.0M | $501.0M | $566.0M | $574.0M | $518.0M |
| Other short-term debt | $320.0M | $160.0M | $755.0M | $567.0M | $50.0M | $56.0M | $157.0M | $29.0M |
| Dividends payable | $2.4B | $0.0 | $2.4B | $0.0 | $2.4B | $0.0 | $2.4B | $0.0 |